Health Canada Authorizes Phase I Clinical Study
JN Nova Pharma has received Health Canada authorization to initiate its first-in-human Phase I clinical study evaluating its proprietary inhaled therapeutic platform.
Media Centre
Advancing Canadian Innovation to Improve Global Health
The JN Nova Pharma Media Centre provides the latest company announcements, clinical development updates, strategic partnerships, publications, media resources, and corporate information.
Media Centre
As a Canadian clinical-stage biotechnology company, JN Nova Pharma is committed to transparent communication as we advance innovative therapeutics for respiratory diseases, inflammatory disorders, infectious diseases, and other high unmet medical needs.